Wells Fargo
BBLG

Wells Fargo’s Bone Biologics BBLG Stock Holding History

Wells Fargo’s Portfolio BBLG Stock Details BBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$9 – 6923
2024
Q1 		$9 Hold
1
– – ﹤0.01% 7305
2023
Q4 		$19 Buy
+1
New +$25 ﹤0.01% 7234
2023
Q3 		– Hold
0
– – – 7274
2023
Q2 		– Hold
0
– – – 7534
2023
Q1 		– Hold
0
– – – 7460
2022
Q4 		– Hold
0
– – – 7373
2022
Q3 		– Hold
0
– – – 6652

Other funds holding BBLG

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
MWA
MFA Wealth Advisors Pittsburgh, Pennsylvania $587M AUM 27.44% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo's BBLG Position: Q2 2024 in Review

Wells Fargo sold out of Bone Biologics (BBLG) in Q2 2024, closing a stake of 1 share — an estimated $9 sold.

Wells Fargo first reported a position in BBLG in Q4 2023 and held it in 2 quarters. The position peaked at $19 in Q4 2023. 5 funds tracked by Wall St. Rank hold BBLG as of Q2 2024.

  • Wells Fargo reported no remaining Bone Biologics position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 1 Bone Biologics share in Q2 2024, an estimated $9.
  • Wells Fargo first reported a position in Bone Biologics in Q4 2023 and held it in 2 quarters.
  • Wells Fargo's Bone Biologics position peaked at $19 in Q4 2023.
  • 5 funds tracked by Wall St. Rank held Bone Biologics as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.